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Are healthcare costs from obesity associated with body
mass index, comorbidity or depression? Cohort study
using electronic health records
C. Rudisill1, J. Charlton2, H. P. Booth2 and M. C. Gulliford2,3
What is already known about this subject?
• Obesity is associated with higher healthcare costs.
• It is less clear whether obesity, or obesity-associated comorbidities
and depression, are the main driver of healthcare costs.
• Few studies have been based on nationally representative data
sources.
What this study adds?
• This study reports data for a large English cohort, with 873 809 person-
years of follow-up.
• Healthcare costs are greater as the BMI category increases, but
comorbidity and depression are the greatest drivers of healthcare
costs in obesity.
• Prioritizing primary prevention of cardiovascular disease and diabetes,
as well as improving depression management in obesity, may contrib-
ute to reducing obesity-related healthcare costs.
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Summary
The objective of this study was to evaluate the association between body mass
index (BMI) and healthcare costs in relation to obesity-related comorbidity and
depression. A population-based cohort study was undertaken in the UK Clinical
Practice Research Datalink (CPRD). A stratiﬁed random sample was taken of par-
ticipants registered with general practices in England in 2008 and 2013. Person
time was classiﬁed by BMI category and morbidity status using ﬁrst diagnosis of
diabetes (T2DM), coronary heart disease (CHD), stroke or malignant neoplasms.
Participants were classiﬁed annually as depressed or not depressed. Costs of
healthcare utilization were calculated from primary care records with linked hos-
pital episode statistics. A two-part model estimated predicted mean annual costs
by age, gender and morbidity status. Linear regression was used to estimate the
effects of BMI category, comorbidity and depression on healthcare costs. The
analysis included 873 809 person-years (62% female) from 250 046 participants.
Annual healthcare costs increased with BMI, to a mean of £456 (95% CI
344–568) higher for BMI ≥40 kg m−2 than for normal weight based on a general
linear model. After adjusting for BMI, the additional cost of comorbidity was
£1366 (£1269–£1463) and depression £1044 (£973–£1115). There was evidence
of interaction so that as the BMI category increased, additional costs of comorbid-
ity (£199, £74–£325) or depression (£116, £16–£216) were greater. High health-
care costs in obesity may be driven by the presence of comorbidity and
depression. Prioritizing primary prevention of cardiovascular disease and diabetes
in the obese population may contribute to reducing obesity-related healthcare
costs.
Keywords: Comorbidity, depression, healthcare costs, obesity.
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Introduction
Obesity is a growing global health concern, accounting for
substantial national healthcare expenditures, with health-
care costs predicted to be higher by around a third in obese
people compared to those of normal weight (1). The associ-
ation between obesity and healthcare costs is well-
documented in international literature. Investigators have
largely used attributable fraction methodology (2,3) and,
more recently, instrumental variable approaches.(4,5).
These studies have estimated the proportion of healthcare
spending on obesity to be around 5%, with results of up to
20% identiﬁed in the United States (4,6). Despite recent
efforts to quantify direct costs associated with obesity, the
mediators underlying this relationship are poorly under-
stood. Given the continued rise in obesity prevalence and
persistence of the condition in individuals (7), the drivers
of obesity-related costs need to be analysed.
The aim of this paper is to investigate the association
between body mass index (BMI) category and healthcare
costs, focusing on the issue of whether BMI category,
obesity-related comorbidity and/or depression most strongly
determines costs related to obesity. Answering this question
may enable better informed efforts to increase the effective-
ness and efﬁciency of the management of obese individuals.
This analysis advances the literature on obesity-related
healthcare costs in three important ways. First, it utilizes data
from a large and nationally representative database. Previous
studies have relied on smaller (4), regional sources (5) of
healthcare data to estimate costs. Secondly, we have con-
trolled for depression separately from other obesity-related
comorbidities. Depression may be associated with higher
costs either in obesity or in comorbidity. We know that the
obese have higher odds of depression (8). This study aimed
to estimate the effect of weight on costs separate from that of
depression. Third, this study offers estimates for patient-level
costs of obesity using individual-level patient data.
Methods
We undertook a population-based cohort study using the
UK Clinical Practice Research Datalink (CPRD) (https://
www.cprd.com). The CPRD collects primary care elec-
tronic health records for 7% of the UK population and is
considered representative of the UK population in terms of
patient demographic characteristics and the size and com-
position of the general practices of reporting data (9). This
research was part of a larger project to evaluate the cost-
effectiveness of bariatric surgery in adults, and participants
aged 20 or older were included.
Study design and participant selection
A cohort of participants was drawn from the CPRD. Parti-
cipants were eligible if they were registered with a CPRD
general practice between 1 January 2008 and 31 December
2013. We evaluated eligible participants’ BMI records
using the categories 18.5–24.9; 25.0–29.9; 30.0–34.9;
35.0–39.9; 40.0–44.9 and 45.0 kg m−2 and above. We
took a random sample of up to 50 000 participants from
each BMI category. This gave a sample of 259 007 partici-
pants; 1819 participants who received bariatric surgery
were excluded, leaving 257 188 participants for further
analysis. For the present analyses, we further restricted the
participants to those registered with CPRD practices in
England that participated in the data linkage scheme, pro-
viding associated data for Hospital Episode Statistics
(HES). This left 250 046 participants for the analysis.
Statistical data analysis
Electronic health records were analysed from the latest of
the date the practice joined CPRD or the patient’s ﬁrst reg-
istration to the earliest of the end of patient registration or
date of death. Person time for men and women was allo-
cated to a BMI category according to the most recent BMI
value, combining BMI records >40 Kg m−2 into a single
group to represent morbid obesity. Comorbidity status was
evaluated using medical diagnoses coded into electronic
health records during general practice consultations. Per-
son time was classiﬁed according to morbidity status using
the ﬁrst diagnosis of type 2 diabetes (T2DM), coronary
heart disease (CHD), stroke or cancer. Depression was re-
evaluated in each year of follow-up, and patients were con-
sidered to have depression if they were diagnosed with
depression during the year or if they were prescribed anti-
depressants in year and were ever diagnosed with depres-
sion. Morbidities, including T2DM (10), CHD (11), stroke
(12) and depression (13) were evaluated using medical
codes reported previously, while cancer diagnoses were
evaluated using codes for malignant neoplasms.
Health care utilization was estimated from participants’
electronic health records with linked hospital episode statis-
tics (HES) data. Primary and secondary care utilization
was evaluated, including primary care consultations at the
practice, by telephone, at home, emergency and out-of-
hours. Secondary care utilization included admissions to
hospital, out-patient, day case and emergency visits. All
drug prescriptions issued by the practice were evaluated.
Utilization rates were calculated using person time at risk.
Age-standardized rates were estimated using direct stand-
ardization and the European Standard Population (ESP)
for reference. The costs of healthcare utilization were eval-
uated for participants by morbidity and depression status
within BMI categories for the period 2008–2013. Initially,
the mean cost per person per year was calculated for each
combination of BMI category and comorbidity status. The
analysis was undertaken from a health service provider per-
spective (UK National Health Service) and did not consider
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indirect costs such as loss of productivity or patient and
carer time.
Unit costs were applied to the categories of healthcare
utilization to estimate healthcare costs. The unit costs were
all taken from reference sources based on UK£ 2013 price
estimates. The Personal Social Service Research Unit
(PSSRU) publication ‘Unit Costs of Health and Social Care
(2013) was used as the reference for all healthcare costs
(14). The same unit costs were applied across different
levels of age group, gender, BMI category and morbidity
status. Primary care general practitioner (GP) consultation,
emergency or out-of-hours, home visit and telephone con-
sultations were priced at £45, £45, £114 and £27, respec-
tively. Unit costs of secondary care in-patient, out-patient,
day-case and emergency visits were priced at £1400, £135,
£697 and £135, respectively. To assess prescription costs,
Gemscript drug codes for prescriptions in the electronic
health records were linked with prescription costs from a
dictionary compiled by RESIP UK (Chertsey, Surrey, UK).
A two-part model (15,16) was used to analyse healthcare
costs. In the ﬁrst stage, a probit model was employed to
estimate the probability of healthcare utilization being non-
zero. In the second stage, a generalized linear model
(GLM), with a log link and gamma errors, was used to
evaluate the distribution of costs in participants who uti-
lized health care. This predicted mean costs of care, as the
product of the probability of utilizing care and mean costs
of care, for men and women in different BMI and morbid-
ity categories for each year of age. In the ﬁnal stage of anal-
ysis, a linear regression model was employed to estimate
the effects of the BMI category, comorbidity and depres-
sion on predicted healthcare costs, controlling for patient
gender and age. Interaction terms for comorbidity and
depression and comorbidity and BMI category were
included. In order to make the data sufﬁciently concise for
presentation, the comorbidities of T2DM, CHD, stroke and
cancer were combined into a single category of ‘comorbid-
ity’ present or absent for the linear regression analysis. All
statistical analyses were performed using Stata 13 for Win-
dows (Stata Corporation, College Station, TX, USA).
Study approval
The research represents part of a study approved by the
Independent Scientiﬁc Advisory Committee (ISAC) of the
Medicines and Healthcare products Regulatory Agency
(MHRA) (ISAC Protocol No. 13–089).
Results
The cohort person-years are presented in Table 1. Women
(62%) contributed more person time than men (38%), but
person time was distributed evenly among age groups and
BMI categories. Diabetes and depression were each preva-
lent in 16% of person-years.
The two-part model used to estimate healthcare costs
is presented in Table 2. Coefﬁcients associated with
making any use of health care (probit model) increased
with BMI category and were also elevated in the presence
of comorbidity. Coefﬁcients associated with healthcare
costs among those utilizing care also increased with
BMI category and were elevated in comorbidity and
depression. Interactions terms for the effect of BMI cate-
gory by comorbidity and comorbidity by depression on
predicted healthcare costs were signiﬁcant in both the
probit and GLM models.
The predicted annual healthcare costs in UK£ by BMI
category, gender, comorbidity and depression status are
presented in Table 3. Overall, there is a largely positive lin-
ear relationship between healthcare costs and BMI cate-
gory. Depression was consistently associated with greater
healthcare costs in all states. Comorbidity was associated
with considerably greater costs at any level of BMI. How-
ever, there are some notable exceptions. Normal weight
was noted to be associated with higher predicted healthcare
costs than overweight. This result is most evident in partici-
pants with T2DM. In men with depression and T2DM,
normal weight participants had the highest estimated cost
of all BMI categories, at £3940 compared to £3796 in the
morbidly obese category. Similarly, in men with stroke and
depression the annual estimated cost was highest in the
normal weight category, at £4442 compared to £4385 in
Table 1 Distribution of person years by body mass index category,
comorbidity and depression
Variable Category Person-years Percent of total
Total 873 809 (100)
Gender Male 335 610 (38)
Female 538 199 (62)
Age group 20–34 118 364 (14)
35–44 151 810 (17)
45–54 170 562 (20)
55–64 170 362 (19)
65–74 143 723 (16)
75–84 90 972 (10)
85+ 28 017 (3)
BMI category 18.5–24.9 130 806 (15)
25.0–29.9 171 622 (20)
30.0–34.9 181 283 (21)
35.0–39.9 173 470 (20)
40.0+ 216 629 (25)
Comorbidity None 573 998 (66)
T2DM 144 089 (16)
CHD 76 144 (9)
Stroke 19 978 (2)
Cancer 59 600 (7)
Depression Not depressed 731 526 (84)
Depressed 142 282 (16)
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the morbidly obese category. Strokes appear to be related
to the highest overall costs with the exception of men who
are not depressed and who have a BMI ≥ 25 who have
been diagnosed with cancer and women who are not
depressed and who are obese and have been diagnosed
with cancer.
Table 4 shows mean differences in healthcare costs esti-
mated from a linear regression model. The presence of a
Table 2 Two-part regression model for healthcare costs (UK£2013)
Predictor Probit model GLM model
Coefﬁcient (95% conﬁdence
interval)
P-Value Coefﬁcient (95% conﬁdence
interval)
P-Value
Age Per year −0.019 (−0.022 to −0.17) <0.001 −0.017 (−0.020 to −0.015)
Age squared 0.00034 (0.00031–0.00037) <0.001 0.00027 (0.00025–0.00030) <0.001
Gender Female 0.033 (0.031–0.034) 0.02 (−0.00 to 0.03) 0.094
BMI category 18.5–24.9 Ref. Ref.
25.0–29.9 0.08 (0.06–0.10) <0.001 0.01 (−0.02 to 0.03) 0.660
30.0–34.9 0.18 (0.16–0.20) <0.001 0.11 (0.08–0.14) <0.001
35.0–39.9 0.21 (0.19–0.23) <0.001 0.18 (0.15–0.21) <0.001
40.0+ 0.25 (0.23–0.27) <0.001 0.29 (0.26–0.32) <0.001
Depression Present 1.68 (1.56–1.80) <0.001 0.61 (0.54–0.67) <0.001
Comorbidity None Ref. Ref.
T2DM 0.64 (0.53–0.75) <0.001 0.84 (0.70–0.98) <0.001
Coronary heart
disease
0.54 (0.44–0.65) <0.001 0.79 (0.69–0.89) <0.001
Stroke 0.35 (0.21–0.49) <0.001 1.01 (0.81–1.21) <0.001
Cancer 0.35 (0.28–0.43) <0.001 0.84 (0.78–0.89) <0.001
BMI*depression χ2 = 11.9, df = 4 0.018 χ2 = 1.6, df = 4 0.810
BMI*comorbidity χ2 = 33.6, df = 16 0.006 χ2 = 54.5, df = 16 <0.001
Comorbidity*depression χ2 = 112.4, df = 4 <0.001 χ2 = 130.1, df = 4 <0.001
BMI, body mass index; CHD, coronary heart disease; Ref., reference category.
Table 3 Predicted annual healthcare costs (UK£ 2013) by BMI category, gender, depression and comorbidity
Gender Depression BMI category (kg m−2)
18.5–24.9 25–29.9 30–34.9 35–39.9 40+
Men Not depressed At risk 997 1016 1134 1206 1376
DM 2471 2242 2267 2356 2559
CHD 2341 2121 2469 2602 2871
Stroke 2864 2551 2882 2962 3074
Cancer 2406 2566 2936 3059 3280
Depressed At risk 1985 1981 2128 2282 2506
DM 3940 3527 3530 3621 3796
CHD 3645 3204 3719 3876 4227
Stroke 4422 3876 4339 4343 4385
Cancer 3458 3690 4097 4227 4274
Women Not depressed At risk 1057 1072 1194 1289 1439
DM 2548 2306 2332 2421 2659
CHD 2421 2177 2537 2667 3061
Stroke 2983 2676 3020 3054 3229
Cancer 2505 2662 3040 3162 3419
Depressed At risk 2040 2029 2225 2441 2602
DM 4007 3588 3617 3786 4055
CHD 3741 3276 3810 4001 4513
Stroke 4492 3969 4407 4528 4750
Cancer 3577 3759 4207 4435 4527
Figures are mean values across ages 20–100 years.
BMI, body mass index; CHD, coronary heart disease; T2DM, diabetes mellitus.
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comorbidity was identiﬁed as the single largest predictor of
healthcare costs, with a £1366 (95% CI £1296–£1463)
mean increase in annual patient costs if morbidity was
present. The second greatest predictor was depression, at
£1044 (£973–£1115) per patient per year. The BMI cate-
gory was positively associated with healthcare costs but at
a much smaller magnitude, with a £456 increase in mor-
bidly obese participants compared to normal weight. Being
overweight did not increase average healthcare costs. The
female gender was related to higher costs but of a lower
magnitude (£113 in females), while the expected increase in
costs with age was observed. Finally, there was evidence of
a multiplicative effect on costs, with the presence of depres-
sion or high BMI alongside a comorbidity. Having depres-
sion alongside a comorbidity was associated with an
additional cost of £243 (£164–£322) per year, while being
obese, severely obese or morbidly obese increased costs by
a further £168, £152 or £199, respectively. Depression had
a greater additive effect on cost in conjunction with a
comorbidity than BMI. The additive cost impact of a
comorbidity was elevated for those at normal weight.
Discussion
This study investigated healthcare costs in relation to BMI
and may be the ﬁrst study to isolate depression as a driver
of costs separate from other common obesity-related mor-
bidities. Previous studies investigating healthcare costs
relating to obesity using patient cohorts have attempted to
estimate the marginal effect of obesity on costs (4,5).
Understanding the causal association between BMI and
healthcare utilization is important, but in the context of
treating patients in a clinical environment, there is little
beneﬁt in divorcing obesity from related morbidities and
socioeconomic factors.
There is a wide variation in cost estimates for obesity
based on population sample studies, ranging from an addi-
tional €160 per year for severe obesity, compared to nor-
mal weight (5), to $2741 for any obesity compared to
normal weight (4). Our ﬁndings estimated an increase of
£146 per year for simple obesity, in comparison with nor-
mal weight, and £456 for morbid obesity. These estimates
were for the inﬂuence of BMI separate from the considera-
tions of obesity-related morbidities and depression.
We found that having a comorbidity was the greatest
predictor of increased healthcare costs at £1366 per year
followed by clinical depression at £1044 per year. Of the
four obesity-related morbidities we assessed, stroke was
found to be associated with the highest absolute costs,
which is likely to result from acute secondary care required
after a stroke. This ﬁnding is supported by a previous
paper that identiﬁed cardiovascular diseases and
Table 4 Estimated effects of gender, age, depression BMI group and comorbidity on annual healthcare costs (UK£ 2013)
Variable Category Adjusted mean difference (£) (95% conﬁdence interval) P-Value
Gender Male Ref.
Female 113 (81–144) <0.001
Age per year 51 (50–52) <0.001
Depression Not depressed Ref.
Depressed 1044 (973–1115) <0.001
BMI category Ref.
25–29 5 (−117 to 107) 0.934
30–34 146 (34–258) 0.011
35–39 280 (168–392) <0.001
40+ 456 (344–568) <0.001
Comorbidity* Absent Ref.
Present 1366 (1269–1463) <0.001
Comorbidity × depression† 243 (164–322) <0.001
Comorbidity × BMI category‡ 18.5–24 232 (106–35) <0.001
25–29 Ref.
30–34 168 (43–293) 0.009
35–39 152 (17–277) 0.017
40+ 199 (74–325) 0.002
BMI category × depression 18.5–24 121 (20–221) 0.018
25–29 Ref.
30–34 76 (−24 to 176) 0.137
35–39 125 (25–225) 0.014
40+ 116 (16–216) 0.024
*Includes T2DM, coronary heart disease, stroke or cancer.
†Additional cost associated with co-occurrence of comorbidity and depression.
‡Additional cost associated with co-occurrence of comorbidity and stated BMI category.
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cardiovascular agents as the biggest drivers of healthcare
claims costs per unit of BMI (17).
We found that depression was the second greatest
driver of costs, and its presence increased costs in all condi-
tions, consistent with a previous investigation
conducted into depression and healthcare utilization (13).
The impact of depression alongside obesity on healthcare
costs has been reported in a previous study based on sec-
ondary care (18). Overall, having an elevated BMI
category in addition to a comorbidity appeared to increase
costs, although having depression was an even greater
contributor to high healthcare costs alongside a comorbid-
ity. Being overweight was not associated with higher
healthcare costs than normal weight. The lack of statisti-
cally signiﬁcant difference in costs between normal and
overweight BMI categories has also been found in other
studies (6,19).
In T2DM, body weight did not appear to be associated
with healthcare costs. This phenomenon has been reported
elsewhere, and the possibility of greater morbidity in dia-
betics who are of normal weight was suggested as an
explanatory factor (20,21). Our analyses did not standard-
ize for the duration of T2DM or the extent of diabetes-
related complications.
This study has a number of strengths that make it a valu-
able addition to the literature on health care-related costs
of obesity. Firstly, it is based on a large, longitudinal,
nationally representative dataset and uses costs associated
directly with provision of care rather than based on insur-
ance claims, which are an indirect measure of morbidity
and may be less accurate. It is also one of few papers to use
clinically measured height and weight values in the calcula-
tion of BMI rather than self-reported values that are prone
to reporting bias (22). This is also the only paper we are
aware of to use UK sample data to estimate the healthcare
costs associated with obesity. One possible limitation of
the study is selection bias from inclusion of participants
with a BMI recorded during a clinical consultation, who
may be more frequent users of healthcare services and
therefore less healthy. Participants’ morbidity status was
classiﬁed using the ﬁrst diagnosis they received, and we
have not accounted for additional diagnoses. The costs
associated with the conditions we have highlighted may
represent costs from multiple morbidities, which are more
frequent in obese patients and we know were present in
18% of the observations (23).
The economics literature has moved towards using an
instrumental variables approach to examine the causal
effect of obesity on medical costs by using the weight of a
biological relative as an instrument (4,5). The argument for
this method is that the instrument predicts the participants’
weight but not their morbidity status, meaning that the
effect of weight on costs can be isolated. Such papers have
found higher healthcare costs for obesity than non-
instrumented methods, so it is possible our models underes-
timate the magnitude of the relationship.
The ﬁndings of this analysis emphasize that healthcare
costs for obesity are largely driven by a few key obesity-
related morbidities and not by high BMI alone. Further
research is now needed to elucidate the costly elements of
these patients’ care and to develop clinical pathways to
manage them more efﬁciently. Persistently high obesity
rates and evidence from the literature (24) suggest that pre-
ventive and reactive treatment strategies for obesity are cur-
rently of limited effectiveness. Until greater success is
observed in lowering obesity levels, the clinical focus
should be on prevention of secondary conditions as a way
of improving the health status of obese patients and lower-
ing resulting costs. Increasing the uptake of successful
T2DM prevention programmes (25) may prove particu-
larly beneﬁcial given the high costs observed across BMI
categories in this analysis. Similarly, successful interven-
tions to focus on the mental health of the obese might also
stem resultant health and non-healthcare costs related to
depression.
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